Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
暂无分享,去创建一个
[1] Deepak L. Bhatt,et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial , 2019, JAMA.
[2] E. Kerwin,et al. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD , 2019, International journal of chronic obstructive pulmonary disease.
[3] C. Vogelmeier,et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study , 2018, International journal of chronic obstructive pulmonary disease.
[4] B. Make,et al. Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI) , 2018, International journal of chronic obstructive pulmonary disease.
[5] C. Vogelmeier,et al. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. , 2017, Respiratory medicine.
[6] E. Kerwin,et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. , 2017, Respiratory medicine.
[7] A. Shukla,et al. Prevalence and etiological profile of chronic obstructive pulmonary disease in nonsmokers , 2017, Lung India : official organ of Indian Chest Society.
[8] M. R. Siddiqui,et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .
[9] N. Leidy,et al. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies , 2016, Respiratory Research.
[10] M. Cazzola,et al. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.
[11] E. Kerwin,et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[12] Dave Singh,et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.
[13] W. Pohl,et al. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD. , 2015, Respiratory medicine.
[14] H. Watz,et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.
[15] E. Bateman,et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study , 2014, BMC Pulmonary Medicine.
[16] E. Kerwin,et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study , 2014, Respiratory Research.
[17] J. Walters,et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.
[18] A. Church,et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.
[19] C. Caracta,et al. Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study , 2013, COPD.
[20] E. Bateman,et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.
[21] D. Tashkin,et al. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.
[22] J. Wedzicha,et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.
[23] E. Bateman,et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.
[24] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[25] B. Celli,et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[26] E. Kerwin,et al. Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I) , 2012, COPD.
[27] B. Make,et al. PRS51 The Development of the Early Morning Symptoms of COPD Instrument (EMSCI) , 2011 .
[28] P. Kardos,et al. Properties of the COPD assessment test in a cross-sectional European study , 2011, European Respiratory Journal.
[29] A. Swensen,et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. , 2011, Respiratory medicine.
[30] N. Leidy,et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] M Cazzola,et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study , 2010, European Respiratory Journal.
[32] M. Cazzola,et al. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.
[33] J. V. van Noord,et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. , 2010, Respiratory medicine.
[34] S. Sentellas,et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[35] J. Walters. COPD - Diagnosis, management and the role of the GP. , 2010, Australian family physician.
[36] S. Salvi,et al. Chronic obstructive pulmonary disease in non-smokers , 2009, The Lancet.
[37] P. Jones,et al. Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.
[38] M. Partridge,et al. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey , 2009, Current medical research and opinion.
[39] E. G. Gil,et al. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. , 2009, International journal of clinical pharmacology and therapeutics.
[40] D. Tashkin,et al. Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.
[41] E. Lopez-Gonzalez,et al. Determinants of Under-Reporting of Adverse Drug Reactions , 2009, Drug safety.
[42] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[43] K. Rabe,et al. Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.
[44] T. Seemungal,et al. COPD exacerbations: defining their cause and prevention , 2007, The Lancet.
[45] J. Wedzicha,et al. What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines , 2007, Thorax.
[46] D. Mannino,et al. Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.
[47] K. R. Chapman,et al. Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.
[48] B. Celli,et al. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. , 2005, The American journal of medicine.
[49] J. V. van Noord,et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.
[50] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[51] J. Wedzicha,et al. COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.
[52] D. Mannino,et al. Characteristics of adults dying with COPD. , 2002, Chest.
[53] R. Pauwels. Global initiative for chronic obstructive lung diseases (GOLD): time to act , 2001, European Respiratory Journal.
[54] R. Dahl,et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[55] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.